GlassScriptPhysician profile
Asha Karippot
NPI 1841485216
$4,464.32
in general payments reported to CMS, 2019-2025
43 companies · $758 in 2025
The $758 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,904 · 2020: $638 · 2021: $277 · 2022: $101 · 2023: $255 · 2024: $532 · 2025: $758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,071.92 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Novartis Pharmaceuticals Corporation | $572.83 | 2019-2025 | |
| Abbvie INC. | $252.18 | 2019-2025 | |
| Seagen INC. | $209.80 | 2019-2021 | |
| Gilead Sciences, INC. | $202.37 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $184.26 | 2019-2025 | Opdivo |
| Genentech USA, INC. | $170.86 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $166.05 | 2019-2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $126.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $123.74 | 2019-2025 | Enhertu, Imfinzi |
| Exelixis INC. | $122.46 | 2020 | |
| Lilly USA, LLC | $99.87 | 2019-2025 | Jaypirca, Verzenio |
| Janssen Biotech, INC. | $89.21 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| Astellas Pharma US INC | $88.31 | 2020-2021 | |
| Kite Pharma, INC. | $85.73 | 2020-2025 | Yescarta |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Karippot listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.